Axa lifted its position in Stemline Therapeutics, Inc. (NASDAQ:STML) by 44.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 629,205 shares of the biopharmaceutical company’s stock after buying an additional 195,022 shares during the quarter. Axa owned about 2.69% of Stemline Therapeutics worth $5,789,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nationwide Fund Advisors grew its stake in shares of Stemline Therapeutics by 7.8% in the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 858 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Stemline Therapeutics by 3.8% in the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stemline Therapeutics in the 1st quarter worth approximately $120,000. State of Wisconsin Investment Board acquired a new stake in Stemline Therapeutics in the 2nd quarter worth approximately $147,000. Finally, UBS Group AG lifted its holdings in Stemline Therapeutics by 130.0% in the 1st quarter. UBS Group AG now owns 26,945 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 15,232 shares during the last quarter. 48.42% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/16/axa-purchases-195022-shares-of-stemline-therapeutics-inc-stml.html.

Stemline Therapeutics, Inc. (STML) opened at 10.35 on Friday. The firm has a 50-day moving average price of $8.74 and a 200 day moving average price of $8.69. The firm’s market cap is $242.76 million. Stemline Therapeutics, Inc. has a 1-year low of $5.50 and a 1-year high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.18). Stemline Therapeutics had a negative net margin of 4,176.84% and a negative return on equity of 67.35%. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. Equities analysts predict that Stemline Therapeutics, Inc. will post ($2.56) earnings per share for the current year.

A number of brokerages have recently commented on STML. Zacks Investment Research lowered Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday. Jefferies Group LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Stemline Therapeutics in a research report on Thursday, May 25th. Finally, ValuEngine cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. Stemline Therapeutics presently has a consensus rating of “Buy” and an average target price of $29.17.

Stemline Therapeutics Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.